[Skip to Navigation]
Views 623
Citations 0
Observation
April 8, 2020

Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies

Author Affiliations
  • 1Division of Dermatology, Washington University in St Louis, St Louis, Missouri
  • 2Boonshoft School of Medicine, Wright State University, Dayton, Ohio
  • 3Siteman Cancer Center, Washington University in St Louis, St Louis, Missouri
  • 4Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri
JAMA Dermatol. 2020;156(5):601-603. doi:10.1001/jamadermatol.2020.0208

Antibody drug conjugate (ADC) therapies are an emerging treatment for hematologic and solid organ malignant tumors. These ADCs are targeted monoclonal antibodies conjugated to a cytotoxic payload, designed to maximize antitumor effect while minimizing toxic effects to normal host tissue.1 We describe a case series of 6 patients who presented with a similar telangiectatic rash after treatment with ADCs containing the cytotoxic payload tesirine.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×